








# REGISTRATION DOSSIERS AVAILABLE

## RETAIL MARKET (WHOLESALE AND PHARMACIES)

MOLECULE	DOSAGE	REFERENCE PRODUCT
<b>Acyclovir</b> Cream Tablets	5 % 800 mg	Zovirax® (Glaxo SmithKline)
<b>Dexketoprofen</b> Solution for injection/Concentrate for solution for infusion	50 mg/2 mL	Enantyum® (Menarini)
<b>Doxazosin</b> Tablets	2 mg, 4 mg	Cardura® (Pfizer) 
<b>Fluoxetine</b> Capsules	20 mg	Prozac® (Lilly)
<b>Gabapentin</b> Tablets Capsules	600 mg, 800 mg 100 mg, 300 mg, 400 mg	Neurontin® (Pfizer) 
<b>Glimepiride</b> Tablets	1 mg, 2 mg, 3 mg, 4 mg, 6 mg	Amaryl® (Aventis Pharma) 
<b>Glucosamine Sulphate</b> Powder for oral solution	1500 mg	Xicil® (Rottapham)
<b>Ibuprofen-lysine</b> Powder for oral solution	400 mg, 600 mg	Algidrin® (Fardi)
<b>Memantine</b> Film-Coated Tablets	10 mg	Axura® (Merz Pharmaceutical)
<b>Mirtazapine</b> Film-coated tablets	15 mg, 30 mg, 45 mg	Rexer® (Organon) 
<b>Pantoprazole</b> Gastro-resistant tablets	20 mg, 40 mg	Pantozol® (Altana Pharma) 
<b>Quetiapine</b> Film-coated tablets	25 mg, 100 mg, 200 mg, 300 mg	Seroquel® (AstraZeneca) 
<b>Venlafaxine</b> IR Tablets	37,5 mg, 50 mg, 75 mg	Effexor® (Wyeth) 

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

April 2010

# REGISTRATION DOSSIERS AVAILABLE

## HOSPITAL MARKET

<b>MOLECULE</b>	<b>DOSAGE</b>	<b>REFERENCE PRODUCT</b>
<b>Acyclovir</b> Lyophilised powder for solution for infusion	250 mg	Zovirax® (Glaxo SmithKline)
<b>Amoxicillin + clavulanic acid</b> Powder for solution for injection	500 mg/50 mg, 1 g/200 mg, 2 g/200 mg	Augmentine® (Glaxo SmithKline)
<b>Cefepime</b> Powder for solution for injection	1 g, 2 g	Maxipime® (Bristol Myers Squibb)
<b>Cefonicid</b> Powder and solvent for solution for injection	500 mg, 1 g	Monocid® (Glaxo SmithKline)
<b>Cefotaxime</b> Powder and solvent for solution for injection Powder and solvent for solution for injection/infusion	100 mg, 250 mg, 500 mg, 1 g 2 g	Claforan® (Aventis Pharma)
<b>Ceftazidime</b> Powder and solvent for solution for injection Powder for solution for infusion	500 mg, 1 g 1 g, 2 g	Fortum® (Glaxo SmithKline)
<b>Ceftriaxone</b> Powder and solvent for solution for injection Powder for solution for infusion	250 mg, 500 mg, 1 g 2 g	Rocephin® (Roche)
<b>Cis-atracurium</b> Solution for injection	2 mg/mL (5 mL and 10 mL), 5 mg/mL (30 mL)	Nimbex® (Glaxo SmithKline)
<b>Cefuroxime (Sodium)</b> Powder and solvent for solution for injection Powder for solution for injection/infusion	250 mg, 750 mg 1500 mg	Zinacef® (Glaxo SmithKline)

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

April 2010

# REGISTRATION DOSSIERS AVAILABLE

## HOSPITAL MARKET


MOLECULE	DOSAGE	REFERENCE PRODUCT
<b>Clindamycin</b> Solution for injection	150 mg/ml (300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml)	<i>Dalacin</i> <sup>®</sup> (Pharmacia&Upjohn)
<b>Dexketoprofen</b> Solution for injection/Concentrate for solution for infusion	50 mg/2 mL	<i>Enantyum</i> <sup>®</sup> (Menarini)
<b>Fluconazole</b> Solution for infusion	2 mg/ml (50 ml, 100 ml)	<i>Diflucan</i> <sup>®</sup> (Pfizer)
<b>Flumazenil</b> Solution for injection	0,1 mg/ ml (5 ml, 10ml)	<i>Anexate</i> <sup>®</sup> (Roche)
<b>Granisetron</b> Concentrate for solution for injection	3 mg/3 ml	<i>Kytril</i> <sup>®</sup> (Roche)
<b>Iron sucrose</b> Solution for injection/concentrate solution for infusion	20 mg/ml	<i>Venofer</i> <sup>®</sup> (Vifor)
<b>Ketorolac Trometamol</b> Solution for injection	30 mg/ml	<i>Toradol</i> <sup>®</sup> (Roche)
<b>Levofloxacin</b> Solution for infusion	5 mg/ml (500 mg/100 ml)	<i>Tavanic</i> <sup>®</sup> (Aventis)
<b>Meropenem</b> Powder for solution for injection	500 mg, 1g	<i>Meropenem</i> <sup>®</sup> (AstraZeneca)
<b>Midazolam</b> Solution for injection	1 mg/ml (5 mg/5 ml), 5 mg/ml (15 mg/3 ml and 50 mg/10 ml)	<i>Hypnovel</i> <sup>®</sup> (Roche)
<b>Pamidronate</b> Lyophilised powder for solution for infusion	15 mg, 30 mg, 60 mg, 90 mg	<i>Aredia</i> <sup>®</sup> (Novartis)

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

April 2010

# REGISTRATION DOSSIERS AVAILABLE

## HOSPITAL MARKET

MOLECULE	DOSAGE	REFERENCE PRODUCT
<b>Pantoprazole</b> Lyophilised powder for solution for injection/infusion	40 mg	<i>Pantocam®</i> , <i>Pantoloc®</i> (Altana Pharma) 
<b>Paracetamol</b> Solution for infusion	10 mg/ml	<i>Perfalgan®</i> (Bristol Myers Squibb)
<b>Phenytoin</b> Solution for injection	100 mg/2 ml 250 mg/5 ml	<i>Phenytoin®</i> (Pfizer/ Rubió)
<b>Piperacillin/Tazobactam</b> Lyophilised powder and solvent for solution for injection Lyophilised powder for solution for injection	2 g/0,25 g, 4 g/0,5 g	<i>Tazobac®</i> (Wyeth)
<b>Remifentanyl</b> Lyophilised powder for solution for injection/infusion	1 mg, 2 mg, 5 mg	<i>Ultiva®</i> (Glaxo SmithKline)
<b>Somatostatin</b> Lyophilised powder and solvent for solution for infusion	0,25 mg, 3 mg	<i>Stilamin®</i> (Serono, IT, NL, CH.) <i>Aminopanc®</i> (UCB, DE.) <i>Modustatine®</i> (Clin Midy, FR.)
<b>Teicoplanina</b> Lyophilised powder and solvent for solution for injection	200 mg, 400 mg	<i>Targocid®</i> (Aventis Pharma)
<b>Vancomycin</b> Lyophilised powder for solution for injection	500 mg, 1 g	<i>Vancocin®</i> (Lilly)
<b>Zidovudine</b> Capsules Oral solution Tablets	100 mg, 250 mg, 300 mg 50 mg/5 ml 300 mg	<i>Retrovir®</i> (Glaxo SmithKline)
<b>Zoledronic</b> Concentrate for solution for infusion	4 mg/5 mL	<i>Zometa®</i> (Novartis)

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

April 2010